(MDGL) Madrigal Pharmaceuticals, Inc. Business Model Canvas Research

In FY2025, Rezdiffra remained the only FDA-approved MASH therapy in the U.S., so Madrigal Pharmaceuticals, Inc. depends on specialty pharmacy and distribution partners to move each prescription through a controlled channel. These partners manage inventory flow, dispensing, and refill continuity, which matters because the product is started and maintained through prescription access.

• 1 FDA-approved U.S. MASH therapy
• Supports patient start and refill flow
• Controls inventory and dispensing

Managed care organizations and pharmacy benefit stakeholders are key gatekeepers for Madrigal Pharmaceuticals, Inc. because MASH uptake depends on formulary placement, prior authorization, and step-therapy rules. These access terms directly shape real-world conversion from prescription intent to paid claims, so payer alignment can move revenue faster than demand alone.

• Formulary access drives starts
• Utilization rules slow conversion
• Reimbursement shapes paid volume

Medical affairs converts REZDIFFRA data into adoption: Madrigal Pharmaceuticals, Inc.'s first FDA-approved MASH therapy, cleared in 2024 for adults with F2-F3 fibrosis, relies on congress data, publications, and real-world evidence to support reimbursement and safe use. In the 1,700-patient MAESTRO-NASH program, this work helps clinicians use the drug correctly.

• Supports reimbursement with evidence
• Explains safe, on-label use
• Builds trust in hepatology and metabolism

Madrigal Pharmaceuticals, Inc. must tightly oversee production, batch release, packaging, and logistics for Rezdiffra, its once-daily oral MASH therapy. Because patients take it chronically, even short supply gaps can disrupt treatment, so quality control and reliable availability are central to commercial execution.

• Control production and batch release
• Protect product quality
• Keep supply uninterrupted
• Support daily chronic use

Madrigal Pharmaceuticals, Inc.’s field, medical, and access teams are key post-launch resources because they turn Rezdiffra science into uptake with prescribers, payers, and patients. In 2025, with one commercial product, these teams were central to scaling market access and keeping reimbursement and education aligned.

• Supports prescribers, payers, patients
• Drives post-launch uptake
• Essential for access and reimbursement

Madrigal Pharmaceuticals, Inc. operates from West Conshohocken, Pennsylvania, and this HQ is the company’s central base for corporate, development, and commercialization work. It keeps leadership, product planning, and launch execution in one place, which matters for a biotech focused on advancing and selling therapies.

• West Conshohocken HQ
• Anchors corporate functions
• Supports development and commercialization

REZDIFFRA is built to change MASH biology, not just ease symptoms: in MAESTRO-NASH, 26% of patients on resmetirom achieved MASH resolution with no worsening of fibrosis at 52 weeks, versus 10% on placebo. That disease-modifying profile targets the scarring that drives long-term liver outcomes.

• 26% MASH resolution
• 52-week biopsy data
• Targets fibrosis progression

The Roche collaboration adds outside validation from a top-tier pharma partner, which helps signal that Madrigal's science can scale beyond Rezdiffra, its only marketed product as of 2026. That kind of backing can lift long-term pipeline confidence, since a partnered platform reduces single-product risk and broadens commercialization reach.

• Roche adds scientific and commercial credibility.
• Supports expansion beyond one product.
• Raises confidence in the pipeline.

Madrigal Pharmaceuticals, Inc. keeps a non-promotional medical affairs exchange with clinicians through data updates, congress activity, and investigator dialogue. That matters in MASH, where Rezdiffra is the first and only FDA-approved therapy, so trust is built by clear science, not sales talk.

• Shares trial and safety updates
• Engages at medical congresses
• Works with investigators
• Supports trust in a new category

Safety follow-up is central to Madrigal Pharmaceuticals, Inc.’s REZDIFFRA commercial use: prescribers need ongoing adverse-event reporting, liver lab checks, and patient check-ins to keep treatment moving. This support builds a long-term relationship, and safety confidence matters because REZDIFFRA was approved in March 2024 and is meant for repeated, chronic use.

• Ongoing AE reporting supports repeat prescribing.

• Monitoring links Company Name to prescribers.

• Safety trust drives chronic-use retention.

Madrigal Pharmaceuticals, Inc. uses digital HCP and patient resources to support education, enrollment, and therapy start for Rezdiffra, the first FDA-approved treatment for MASH, approved in March 2024. In a narrow specialty market, online tools can cut onboarding friction and speed access, especially when only one branded therapy is being launched.

• Supports HCP education
• Speeds patient enrollment
• Reduces onboarding friction
• Extends reach in specialty care

Scientific meetings and peer-reviewed journals are a key Channel for Madrigal Pharmaceuticals, Inc. because they shape specialist awareness and trust in an evidence-driven disease area. In MASH, where about 1 in 20 U.S. adults are affected, congress data and publications help turn clinical results into prescriber confidence.

• Builds specialist awareness fast
• Reinforces peer-reviewed credibility
• Supports evidence-based adoption

Gastroenterologists are a core launch segment for Madrigal Pharmaceuticals, Inc. because they already manage many metabolic dysfunction-associated steatohepatitis (MASH) patients, and they drive diagnosis, fibrosis staging, and treatment start. MASH is estimated to affect about 5% of U.S. adults, and REZDIFFRA was the first FDA-approved therapy for noncirrhotic MASH with moderate to advanced fibrosis, approved in March 2024.

• Large MASH patient flow
• Controls staging decisions
• Starts treatment early

Payers and pharmacy benefit managers drive Madrigal Pharmaceuticals, Inc.'s access because they decide whether REZDIFFRA is covered, at what tier, and with what prior-authorization rules. In a U.S. market where PBMs manage most prescription claims, these economic gatekeepers can lift or limit utilization far more than end-patient demand alone.

• Coverage rules shape starts and renewals.
• PBMs decide net access, not patients.
• Utilization rises when restrictions ease.

Regulatory and safety operations are a recurring cost for Madrigal Pharmaceuticals, Inc. because Rezdiffra is already marketed, so post-approval monitoring, adverse-event reporting, and compliance work never stop. Madrigal must keep regulatory staff and data systems in place, and this is a normal cost base for a commercial biopharma.

• Ongoing safety reporting is mandatory.

• Regulatory staff must stay on payroll.

• Data systems support compliance tracking.

• Costs rise with label expansion.

General and administrative overhead at Madrigal Pharmaceuticals, Inc. covers finance, legal, HR, and investor relations, plus patent upkeep and collaboration admin. In 2025, this cost base stayed tied to Rezdiffra’s U.S. launch and HQ operations in Pennsylvania, so it matters more as sales scale and compliance work grows.

• Finance, legal, HR, IR
• IP and collaboration admin
• Pennsylvania HQ support
• Launch-linked overhead in 2025

Royalty income from partnered programs can give Madrigal Pharmaceuticals, Inc. high-margin cash flow without funding full sales force, manufacturing, or market launch costs. If a partnered asset scales well, those royalties can become a meaningful second revenue leg alongside the Company’s core liver franchise.

• High-margin partner cash flow
• Less direct launch risk
• Upside grows with partner success

Future licensing and territory deals could add upfront cash, milestone payments, and double-digit royalties for Madrigal Pharmaceuticals, Inc., giving the Company a revenue stream beyond the U.S. Rezdiffra launch, which drove 2024 net product sales of $137.0 million. As of 2025, no major ex-U.S. licensing revenue has been reported, so this remains an option-value stream, not core revenue.

• Upfront fees lift near-term cash
• Royalties scale with partner sales
• Expands beyond the U.S. market